Choose a language and wait for the translated text.
Shots:
Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics to develop, manufacture & commercialize 3 pre-IND in vivo CAR-T programs for autoimmune diseases outside Greater China
Starna will receive $330M upfront & is eligible for up to $2.3B in development & commercial milestones, plus royalties on net sales; Pfizer will lead clinical development outside Greater China & holds options to expand its territory to Greater China
Pfizer also receives rights to use Starnaβs in vivo CAR-T technology in I&I and oncology, along with options to license compounds from a separate research collaboration
Ref: Pfizer | Image: Pfizer | Starna Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Pfizer Enters into an Exclusive Licensing Agreement with Starna Therapeutics for In Vivo CAR-T Programs in Autoimmune Diseases appeared first on PharmaShots.